Preliminary data from a phase I study evaluating the novel antibody-drug conjugate M9140 demonstrated encouraging activity in heavily pretreated patients with advanced colorectal cancer. The study was presented by principal investigator Scott Kopetz, professor of gastrointestinal medical oncology and associate vice president for Translational Integration at MD Anderson, at the 2024 American Society of Clinical Oncology Annual Meeting.
Preliminary data from the first-in-human phase I trial of RO7623066—a first-in-class inhibitor of ubiquitin-specific peptidase 1—show a promising safety profile as a single agent and signs of early anti-tumor activity for patients with advanced solid tumors. The data were presented by Timothy Yap, professor of investigational cancer therapeutics and vice president and head of clinical development in MD Anderson’s Therapeutics Discovery division, at the 2024 American Society of Clinical Oncology Annual Meeting.
Renée and Robert BelferLaurence Belfer, on behalf of Robert Belfer and the Belfer family, will give $20 million to MD Anderson Cancer Center to strengthen neurodegeneration research through the Belfer Neurodegeneration Consortium, a transformative multi-institutional initiative to advance the study and treatment of Alzheimer’s disease.
MD Anderson Cancer Center and the Pan American Health Organization are collaborating to strengthen cancer prevention and control initiatives across the Americas.
A national study led by researchers at MD Anderson Cancer Center and the University of New Mexico Comprehensive Cancer Center found major gaps in breast, cervical, and colorectal cancer screening use in Federally Qualified Health Centers in the US, relative to overall screening rates in the country.
MD Anderson Cancer Center and RUSH University System for Health are collaborating to create RUSH MD Anderson Cancer Center.
MD Anderson Cancer Center and CureVac N.V. are entering a co-development and licensing agreement to develop novel mRNA-based cancer vaccines.
MD Anderson Cancer Center and C-Biomex Ltd. have formed a strategic research collaboration agreement to co-develop CBT-001, a radioligand targeting the CA9 cancer biomarker.
MD Anderson Cancer Center has signed an agreement with the International Atomic Energy Agency to become an IAEA Collaborating Centre.
We unexpectedly lost a dear friend and colleague, Dr. Cullen Taniguchi, in mid-November. Dr. Taniguchi was an exceptional and compassionate clinician, brilliant scientist, and nurturing mentor. Above all, he was a dedicated and loving husband, father, son, and brother. We deeply mourn his loss, but we forever cherish the memories and indelible legacy that he leaves with us.
